nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—Cytarabine—Gemcitabine—kidney cancer	0.15	0.513	CrCrCtD
Fludarabine—Azacitidine—Gemcitabine—kidney cancer	0.142	0.487	CrCrCtD
Fludarabine—RRM1—Gemcitabine—kidney cancer	0.134	0.261	CbGbCtD
Fludarabine—POLA1—Gemcitabine—kidney cancer	0.116	0.225	CbGbCtD
Fludarabine—SLC28A3—Gemcitabine—kidney cancer	0.116	0.225	CbGbCtD
Fludarabine—SLC29A1—Gemcitabine—kidney cancer	0.0768	0.15	CbGbCtD
Fludarabine—DCK—Gemcitabine—kidney cancer	0.0712	0.139	CbGbCtD
Fludarabine—DCK—Purine salvage—APRT—kidney cancer	0.0031	0.0804	CbGpPWpGaD
Fludarabine—RRM1—Fluoropyrimidine Activity—PPAT—kidney cancer	0.00206	0.0533	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—PPAT—kidney cancer	0.00188	0.0488	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—HLTF—kidney cancer	0.0018	0.0467	CbGpPWpGaD
Fludarabine—DCK—Purine metabolism—PPAT—kidney cancer	0.00158	0.041	CbGpPWpGaD
Fludarabine—DCK—Purine metabolism—APRT—kidney cancer	0.00147	0.0381	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—HLTF—kidney cancer	0.00139	0.036	CbGpPWpGaD
Fludarabine—Adenosine triphosphate—APAF1—kidney cancer	0.00121	0.468	CrCbGaD
Fludarabine—RRM1—E2F transcription factor network—TFE3—kidney cancer	0.00114	0.0295	CbGpPWpGaD
Fludarabine—RRM1—nephron tubule—kidney cancer	0.00109	0.0873	CbGeAlD
Fludarabine—RRM1—Nucleotide metabolism—PPAT—kidney cancer	0.00103	0.0268	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—HLTF—kidney cancer	0.00102	0.0263	CbGpPWpGaD
Fludarabine—RRM1—renal system—kidney cancer	0.000993	0.0793	CbGeAlD
Fludarabine—RRM1—Nucleotide metabolism—APRT—kidney cancer	0.000961	0.0249	CbGpPWpGaD
Fludarabine—RRM1—kidney—kidney cancer	0.00096	0.0767	CbGeAlD
Fludarabine—RRM1—cortex of kidney—kidney cancer	0.000935	0.0747	CbGeAlD
Fludarabine—Adenosine monophosphate—APRT—kidney cancer	0.000901	0.347	CrCbGaD
Fludarabine—RRM1—gonad—kidney cancer	0.000891	0.0712	CbGeAlD
Fludarabine—RRM1—cardiac atrium—kidney cancer	0.000889	0.0711	CbGeAlD
Fludarabine—DCK—nephron tubule—kidney cancer	0.000849	0.0678	CbGeAlD
Fludarabine—SLC29A1—renal system—kidney cancer	0.000808	0.0645	CbGeAlD
Fludarabine—DCK—Nucleotide metabolism—PPAT—kidney cancer	0.000796	0.0206	CbGpPWpGaD
Fludarabine—SLC29A1—kidney—kidney cancer	0.000781	0.0624	CbGeAlD
Fludarabine—SLC29A1—cortex of kidney—kidney cancer	0.00076	0.0607	CbGeAlD
Fludarabine—DCK—Nucleotide metabolism—APRT—kidney cancer	0.00074	0.0192	CbGpPWpGaD
Fludarabine—DCK—cortex of kidney—kidney cancer	0.000726	0.058	CbGeAlD
Fludarabine—SLC29A1—gonad—kidney cancer	0.000724	0.0579	CbGeAlD
Fludarabine—SLC29A1—cardiac atrium—kidney cancer	0.000723	0.0578	CbGeAlD
Fludarabine—DCK—gonad—kidney cancer	0.000692	0.0553	CbGeAlD
Fludarabine—DCK—cardiac atrium—kidney cancer	0.000691	0.0552	CbGeAlD
Fludarabine—POLA1—Vinblastine—Vincristine—kidney cancer	0.000662	0.266	CbGdCrCtD
Fludarabine—POLA1—E2F transcription factor network—TFE3—kidney cancer	0.000641	0.0166	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—APAF1—kidney cancer	0.000614	0.0159	CbGpPWpGaD
Fludarabine—DCK—Sirolimus—Everolimus—kidney cancer	0.000594	0.239	CbGdCrCtD
Fludarabine—DCK—Sirolimus—Temsirolimus—kidney cancer	0.000594	0.239	CbGdCrCtD
Fludarabine—RRM1—Azacitidine—Gemcitabine—kidney cancer	0.000449	0.18	CbGdCrCtD
Fludarabine—Adenosine triphosphate—ALK—kidney cancer	0.000422	0.163	CrCbGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000367	0.00951	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—APAF1—kidney cancer	0.000346	0.00896	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000325	0.00841	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	0.000285	0.00737	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	0.000285	0.00737	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000274	0.00709	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	0.00027	0.00699	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000242	0.00627	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication Pre-Initiation—PSMD7—kidney cancer	0.000241	0.00625	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	0.000235	0.00608	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	0.000216	0.00559	CbGpPWpGaD
Fludarabine—POLA1—Synthesis of DNA—PSMD7—kidney cancer	0.000211	0.00546	CbGpPWpGaD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—kidney cancer	0.000204	0.00529	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—PSMD7—kidney cancer	0.000198	0.00512	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—CDKN2A—kidney cancer	0.000195	0.00504	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	0.000194	0.00502	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	0.000194	0.00502	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000194	0.00501	CbGpPWpGaD
Fludarabine—DCK—Epirubicin—Doxorubicin—kidney cancer	0.000191	0.0768	CbGdCrCtD
Fludarabine—POLA1—G1/S Transition—PSMD7—kidney cancer	0.00019	0.00493	CbGpPWpGaD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000187	0.00484	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—kidney cancer	0.000187	0.00484	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000186	0.00483	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000186	0.00483	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000186	0.00483	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	0.000181	0.00469	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—SYNE2—kidney cancer	0.000178	0.0046	CbGpPWpGaD
Fludarabine—POLA1—S Phase—PSMD7—kidney cancer	0.000173	0.00447	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—CDKN1B—kidney cancer	0.000172	0.00446	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—RAF1—kidney cancer	0.000163	0.00423	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—PSMD7—kidney cancer	0.00016	0.00415	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	0.00016	0.00415	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	0.00016	0.00415	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	0.000159	0.00412	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	0.000158	0.00408	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	0.000154	0.00399	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	0.000152	0.00394	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CDKN1B—kidney cancer	0.00015	0.00388	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000144	0.00374	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—kidney cancer	0.000143	0.0037	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000139	0.00361	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000139	0.0036	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000139	0.0036	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000139	0.0036	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ACY1—kidney cancer	0.000136	0.00351	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	0.000132	0.00342	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—MYC—kidney cancer	0.000132	0.00342	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—RAF1—kidney cancer	0.000126	0.00326	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	0.000121	0.00315	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN2B—kidney cancer	0.000117	0.00304	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PDHB—kidney cancer	0.000115	0.00299	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1B—kidney cancer	0.000115	0.00299	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—MYC—kidney cancer	0.000115	0.00297	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	0.000111	0.00288	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—kidney cancer	0.00011	0.00285	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—CDKN2A—kidney cancer	0.00011	0.00284	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	0.000109	0.00283	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	0.000109	0.00283	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CCBL1—kidney cancer	0.000108	0.00281	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ACY1—kidney cancer	0.000104	0.0027	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	0.000102	0.00264	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	9.83e-05	0.00255	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—CDKN1B—kidney cancer	9.7e-05	0.00251	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	9.5e-05	0.00246	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—kidney cancer	9.41e-05	0.00244	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GLIPR1—kidney cancer	9.39e-05	0.00243	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PPAT—kidney cancer	9.39e-05	0.00243	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—RAF1—kidney cancer	9.2e-05	0.00238	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	8.95e-05	0.00232	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	8.88e-05	0.0023	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PDHB—kidney cancer	8.87e-05	0.0023	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—kidney cancer	8.82e-05	0.00228	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—FH—kidney cancer	8.73e-05	0.00226	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—APRT—kidney cancer	8.73e-05	0.00226	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	8.71e-05	0.00226	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABCB1—kidney cancer	8.67e-05	0.00225	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	8.62e-05	0.00223	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1B—kidney cancer	8.43e-05	0.00218	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	8.43e-05	0.00218	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CCBL1—kidney cancer	8.34e-05	0.00216	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GPC3—kidney cancer	8.21e-05	0.00213	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—kidney cancer	8.04e-05	0.00208	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CA2—kidney cancer	7.99e-05	0.00207	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	7.98e-05	0.00207	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—PSMD7—kidney cancer	7.86e-05	0.00204	CbGpPWpGaD
Fludarabine—POLA1—Synthesis of DNA—CDKN1B—kidney cancer	7.79e-05	0.00202	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ALAD—kidney cancer	7.78e-05	0.00202	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	7.61e-05	0.00197	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ST3GAL2—kidney cancer	7.6e-05	0.00197	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	7.6e-05	0.00197	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	7.54e-05	0.00195	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	7.5e-05	0.00194	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ALDH1A1—kidney cancer	7.43e-05	0.00192	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—MYC—kidney cancer	7.42e-05	0.00192	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	7.35e-05	0.0019	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	7.33e-05	0.0019	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—CDKN1B—kidney cancer	7.31e-05	0.00189	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—kidney cancer	7.24e-05	0.00188	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GLIPR1—kidney cancer	7.23e-05	0.00187	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PPAT—kidney cancer	7.23e-05	0.00187	CbGpPWpGaD
Fludarabine—Haematuria—Capecitabine—kidney cancer	7.14e-05	0.000514	CcSEcCtD
Fludarabine—Malnutrition—Paclitaxel—kidney cancer	7.14e-05	0.000513	CcSEcCtD
Fludarabine—Decreased appetite—Dactinomycin—kidney cancer	7.13e-05	0.000513	CcSEcCtD
Fludarabine—Diarrhoea—Vinblastine—kidney cancer	7.13e-05	0.000512	CcSEcCtD
Fludarabine—Body temperature increased—Sorafenib—kidney cancer	7.12e-05	0.000512	CcSEcCtD
Fludarabine—RRM1—Metabolism—SLC5A3—kidney cancer	7.12e-05	0.00184	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PGK1—kidney cancer	7.12e-05	0.00184	CbGpPWpGaD
Fludarabine—Diarrhoea—Everolimus—kidney cancer	7.1e-05	0.00051	CcSEcCtD
Fludarabine—Hyperhidrosis—Vincristine—kidney cancer	7.09e-05	0.00051	CcSEcCtD
Fludarabine—Pruritus—Erlotinib—kidney cancer	7.08e-05	0.000509	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	7.08e-05	0.00183	CbGpPWpGaD
Fludarabine—Fatigue—Dactinomycin—kidney cancer	7.08e-05	0.000509	CcSEcCtD
Fludarabine—Epistaxis—Capecitabine—kidney cancer	7.07e-05	0.000508	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—CDKN1B—kidney cancer	7.04e-05	0.00182	CbGpPWpGaD
Fludarabine—Pain—Dactinomycin—kidney cancer	7.02e-05	0.000505	CcSEcCtD
Fludarabine—Anorexia—Vincristine—kidney cancer	6.99e-05	0.000502	CcSEcCtD
Fludarabine—RRM1—Metabolism—LDHB—kidney cancer	6.98e-05	0.00181	CbGpPWpGaD
Fludarabine—Hepatic failure—Doxorubicin—kidney cancer	6.97e-05	0.000501	CcSEcCtD
Fludarabine—Oedema—Gemcitabine—kidney cancer	6.96e-05	0.0005	CcSEcCtD
Fludarabine—Anaphylactic shock—Gemcitabine—kidney cancer	6.96e-05	0.0005	CcSEcCtD
Fludarabine—Cardiac failure congestive—Doxorubicin—kidney cancer	6.91e-05	0.000497	CcSEcCtD
Fludarabine—Infection—Gemcitabine—kidney cancer	6.91e-05	0.000497	CcSEcCtD
Fludarabine—Body temperature increased—Sunitinib—kidney cancer	6.85e-05	0.000493	CcSEcCtD
Fludarabine—Diarrhoea—Erlotinib—kidney cancer	6.85e-05	0.000493	CcSEcCtD
Fludarabine—Nervous system disorder—Gemcitabine—kidney cancer	6.82e-05	0.00049	CcSEcCtD
Fludarabine—Thrombocytopenia—Gemcitabine—kidney cancer	6.81e-05	0.00049	CcSEcCtD
Fludarabine—Feeling abnormal—Dactinomycin—kidney cancer	6.76e-05	0.000486	CcSEcCtD
Fludarabine—Haemoglobin—Capecitabine—kidney cancer	6.76e-05	0.000486	CcSEcCtD
Fludarabine—Haemorrhage—Capecitabine—kidney cancer	6.73e-05	0.000484	CcSEcCtD
Fludarabine—Hyperhidrosis—Gemcitabine—kidney cancer	6.72e-05	0.000483	CcSEcCtD
Fludarabine—DCK—Metabolism—APRT—kidney cancer	6.72e-05	0.00174	CbGpPWpGaD
Fludarabine—DCK—Metabolism—FH—kidney cancer	6.72e-05	0.00174	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—kidney cancer	6.7e-05	0.00174	CbGpPWpGaD
Fludarabine—Hypoaesthesia—Capecitabine—kidney cancer	6.69e-05	0.000481	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Vincristine—kidney cancer	6.68e-05	0.00048	CcSEcCtD
Fludarabine—Pharyngitis—Capecitabine—kidney cancer	6.68e-05	0.00048	CcSEcCtD
Fludarabine—Hypersensitivity—Sorafenib—kidney cancer	6.64e-05	0.000477	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	6.64e-05	0.00172	CbGpPWpGaD
Fludarabine—Anorexia—Gemcitabine—kidney cancer	6.63e-05	0.000477	CcSEcCtD
Fludarabine—Vomiting—Vinblastine—kidney cancer	6.62e-05	0.000476	CcSEcCtD
Fludarabine—Ill-defined disorder—Paclitaxel—kidney cancer	6.62e-05	0.000476	CcSEcCtD
Fludarabine—Vomiting—Everolimus—kidney cancer	6.6e-05	0.000474	CcSEcCtD
Fludarabine—Anaemia—Paclitaxel—kidney cancer	6.6e-05	0.000474	CcSEcCtD
Fludarabine—Paraesthesia—Vincristine—kidney cancer	6.58e-05	0.000473	CcSEcCtD
Fludarabine—Agitation—Paclitaxel—kidney cancer	6.56e-05	0.000471	CcSEcCtD
Fludarabine—Rash—Everolimus—kidney cancer	6.54e-05	0.00047	CcSEcCtD
Fludarabine—Dermatitis—Everolimus—kidney cancer	6.54e-05	0.00047	CcSEcCtD
Fludarabine—Headache—Vinblastine—kidney cancer	6.53e-05	0.000469	CcSEcCtD
Fludarabine—Headache—Everolimus—kidney cancer	6.5e-05	0.000467	CcSEcCtD
Fludarabine—Body temperature increased—Dactinomycin—kidney cancer	6.49e-05	0.000466	CcSEcCtD
Fludarabine—Visual impairment—Capecitabine—kidney cancer	6.48e-05	0.000466	CcSEcCtD
Fludarabine—Asthenia—Sorafenib—kidney cancer	6.46e-05	0.000465	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—kidney cancer	6.45e-05	0.00167	CbGpPWpGaD
Fludarabine—Malaise—Paclitaxel—kidney cancer	6.43e-05	0.000463	CcSEcCtD
Fludarabine—Cardiac failure—Doxorubicin—kidney cancer	6.42e-05	0.000462	CcSEcCtD
Fludarabine—Cerebrovascular accident—Doxorubicin—kidney cancer	6.4e-05	0.00046	CcSEcCtD
Fludarabine—POLA1—S Phase—CDKN1B—kidney cancer	6.39e-05	0.00166	CbGpPWpGaD
Fludarabine—Leukopenia—Paclitaxel—kidney cancer	6.39e-05	0.000459	CcSEcCtD
Fludarabine—Hypersensitivity—Sunitinib—kidney cancer	6.39e-05	0.000459	CcSEcCtD
Fludarabine—Decreased appetite—Vincristine—kidney cancer	6.37e-05	0.000458	CcSEcCtD
Fludarabine—Pruritus—Sorafenib—kidney cancer	6.37e-05	0.000458	CcSEcCtD
Fludarabine—Vomiting—Erlotinib—kidney cancer	6.37e-05	0.000458	CcSEcCtD
Fludarabine—Erythema multiforme—Capecitabine—kidney cancer	6.36e-05	0.000457	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	6.34e-05	0.000456	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Vincristine—kidney cancer	6.33e-05	0.000455	CcSEcCtD
Fludarabine—Fatigue—Vincristine—kidney cancer	6.32e-05	0.000454	CcSEcCtD
Fludarabine—DCK—Metabolism—GPC3—kidney cancer	6.32e-05	0.00164	CbGpPWpGaD
Fludarabine—Rash—Erlotinib—kidney cancer	6.31e-05	0.000454	CcSEcCtD
Fludarabine—Dermatitis—Erlotinib—kidney cancer	6.31e-05	0.000453	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	6.28e-05	0.00163	CbGpPWpGaD
Fludarabine—Headache—Erlotinib—kidney cancer	6.27e-05	0.000451	CcSEcCtD
Fludarabine—Pain—Vincristine—kidney cancer	6.27e-05	0.000451	CcSEcCtD
Fludarabine—Constipation—Vincristine—kidney cancer	6.27e-05	0.000451	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	6.27e-05	0.000451	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	6.25e-05	0.00162	CbGpPWpGaD
Fludarabine—Paraesthesia—Gemcitabine—kidney cancer	6.25e-05	0.000449	CcSEcCtD
Fludarabine—Cough—Paclitaxel—kidney cancer	6.23e-05	0.000448	CcSEcCtD
Fludarabine—Asthenia—Sunitinib—kidney cancer	6.22e-05	0.000447	CcSEcCtD
Fludarabine—Dyspnoea—Gemcitabine—kidney cancer	6.2e-05	0.000446	CcSEcCtD
Fludarabine—Nausea—Vinblastine—kidney cancer	6.19e-05	0.000445	CcSEcCtD
Fludarabine—Convulsion—Paclitaxel—kidney cancer	6.18e-05	0.000444	CcSEcCtD
Fludarabine—Nausea—Everolimus—kidney cancer	6.16e-05	0.000443	CcSEcCtD
Fludarabine—Diarrhoea—Sorafenib—kidney cancer	6.16e-05	0.000443	CcSEcCtD
Fludarabine—DCK—Metabolism—CA2—kidney cancer	6.15e-05	0.00159	CbGpPWpGaD
Fludarabine—Pruritus—Sunitinib—kidney cancer	6.13e-05	0.000441	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	6.11e-05	0.00158	CbGpPWpGaD
Fludarabine—POLA1—S Phase—CCND1—kidney cancer	6.1e-05	0.00158	CbGpPWpGaD
Fludarabine—Myalgia—Paclitaxel—kidney cancer	6.08e-05	0.000437	CcSEcCtD
Fludarabine—Arthralgia—Paclitaxel—kidney cancer	6.08e-05	0.000437	CcSEcCtD
Fludarabine—RRM1—Metabolism—CA9—kidney cancer	6.05e-05	0.00157	CbGpPWpGaD
Fludarabine—Decreased appetite—Gemcitabine—kidney cancer	6.05e-05	0.000435	CcSEcCtD
Fludarabine—Hypersensitivity—Dactinomycin—kidney cancer	6.05e-05	0.000435	CcSEcCtD
Fludarabine—Chills—Capecitabine—kidney cancer	6.04e-05	0.000434	CcSEcCtD
Fludarabine—Arrhythmia—Capecitabine—kidney cancer	6.01e-05	0.000432	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Gemcitabine—kidney cancer	6.01e-05	0.000432	CcSEcCtD
Fludarabine—Discomfort—Paclitaxel—kidney cancer	6e-05	0.000431	CcSEcCtD
Fludarabine—Fatigue—Gemcitabine—kidney cancer	6e-05	0.000431	CcSEcCtD
Fludarabine—DCK—Metabolism—ALAD—kidney cancer	5.99e-05	0.00155	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	5.97e-05	0.00155	CbGpPWpGaD
Fludarabine—Pain—Gemcitabine—kidney cancer	5.95e-05	0.000428	CcSEcCtD
Fludarabine—Constipation—Gemcitabine—kidney cancer	5.95e-05	0.000428	CcSEcCtD
Fludarabine—Nausea—Erlotinib—kidney cancer	5.95e-05	0.000428	CcSEcCtD
Fludarabine—Alopecia—Capecitabine—kidney cancer	5.94e-05	0.000427	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN1B—kidney cancer	5.93e-05	0.00154	CbGpPWpGaD
Fludarabine—Diarrhoea—Sunitinib—kidney cancer	5.93e-05	0.000426	CcSEcCtD
Fludarabine—Asthenia—Dactinomycin—kidney cancer	5.89e-05	0.000423	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—PSMD7—kidney cancer	5.88e-05	0.00152	CbGpPWpGaD
Fludarabine—Confusional state—Paclitaxel—kidney cancer	5.87e-05	0.000422	CcSEcCtD
Fludarabine—Malnutrition—Capecitabine—kidney cancer	5.86e-05	0.000421	CcSEcCtD
Fludarabine—DCK—Metabolism—ST3GAL2—kidney cancer	5.85e-05	0.00151	CbGpPWpGaD
Fludarabine—Dehydration—Doxorubicin—kidney cancer	5.83e-05	0.000419	CcSEcCtD
Fludarabine—Anaphylactic shock—Paclitaxel—kidney cancer	5.82e-05	0.000419	CcSEcCtD
Fludarabine—Oedema—Paclitaxel—kidney cancer	5.82e-05	0.000419	CcSEcCtD
Fludarabine—Body temperature increased—Vincristine—kidney cancer	5.8e-05	0.000417	CcSEcCtD
Fludarabine—Liver function test abnormal—Doxorubicin—kidney cancer	5.79e-05	0.000416	CcSEcCtD
Fludarabine—Infection—Paclitaxel—kidney cancer	5.79e-05	0.000416	CcSEcCtD
Fludarabine—Adenosine triphosphate—ABCB1—kidney cancer	5.75e-05	0.0222	CrCbGaD
Fludarabine—Feeling abnormal—Gemcitabine—kidney cancer	5.73e-05	0.000412	CcSEcCtD
Fludarabine—Vomiting—Sorafenib—kidney cancer	5.73e-05	0.000412	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—AURKA—kidney cancer	5.72e-05	0.00148	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ALDH1A1—kidney cancer	5.71e-05	0.00148	CbGpPWpGaD
Fludarabine—Nervous system disorder—Paclitaxel—kidney cancer	5.71e-05	0.000411	CcSEcCtD
Fludarabine—Thrombocytopenia—Paclitaxel—kidney cancer	5.7e-05	0.00041	CcSEcCtD
Fludarabine—Rash—Sorafenib—kidney cancer	5.68e-05	0.000408	CcSEcCtD
Fludarabine—Dermatitis—Sorafenib—kidney cancer	5.68e-05	0.000408	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CCND1—kidney cancer	5.66e-05	0.00147	CbGpPWpGaD
Fludarabine—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	5.64e-05	0.000406	CcSEcCtD
Fludarabine—Headache—Sorafenib—kidney cancer	5.64e-05	0.000406	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	5.64e-05	0.00146	CbGpPWpGaD
Fludarabine—Hyperhidrosis—Paclitaxel—kidney cancer	5.63e-05	0.000405	CcSEcCtD
Fludarabine—Diarrhoea—Dactinomycin—kidney cancer	5.62e-05	0.000404	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ABCB1—kidney cancer	5.59e-05	0.00145	CbGpPWpGaD
Fludarabine—Anorexia—Paclitaxel—kidney cancer	5.55e-05	0.000399	CcSEcCtD
Fludarabine—Vomiting—Sunitinib—kidney cancer	5.51e-05	0.000396	CcSEcCtD
Fludarabine—Body temperature increased—Gemcitabine—kidney cancer	5.5e-05	0.000395	CcSEcCtD
Fludarabine—DCK—Metabolism—SLC5A3—kidney cancer	5.48e-05	0.00142	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PGK1—kidney cancer	5.48e-05	0.00142	CbGpPWpGaD
Fludarabine—Rash—Sunitinib—kidney cancer	5.47e-05	0.000393	CcSEcCtD
Fludarabine—Dermatitis—Sunitinib—kidney cancer	5.46e-05	0.000393	CcSEcCtD
Fludarabine—Ill-defined disorder—Capecitabine—kidney cancer	5.43e-05	0.000391	CcSEcCtD
Fludarabine—Headache—Sunitinib—kidney cancer	5.43e-05	0.00039	CcSEcCtD
Fludarabine—Dysphagia—Doxorubicin—kidney cancer	5.42e-05	0.000389	CcSEcCtD
Fludarabine—Anaemia—Capecitabine—kidney cancer	5.41e-05	0.000389	CcSEcCtD
Fludarabine—Hypersensitivity—Vincristine—kidney cancer	5.4e-05	0.000388	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—MYC—kidney cancer	5.39e-05	0.0014	CbGpPWpGaD
Fludarabine—DCK—Metabolism—LDHB—kidney cancer	5.37e-05	0.00139	CbGpPWpGaD
Fludarabine—Nausea—Sorafenib—kidney cancer	5.35e-05	0.000385	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	5.31e-05	0.000381	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—kidney cancer	5.3e-05	0.00137	CbGpPWpGaD
Fludarabine—Malaise—Capecitabine—kidney cancer	5.28e-05	0.00038	CcSEcCtD
Fludarabine—Angina pectoris—Doxorubicin—kidney cancer	5.28e-05	0.000379	CcSEcCtD
Fludarabine—Asthenia—Vincristine—kidney cancer	5.26e-05	0.000378	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—PSMD7—kidney cancer	5.26e-05	0.00136	CbGpPWpGaD
Fludarabine—Leukopenia—Capecitabine—kidney cancer	5.24e-05	0.000377	CcSEcCtD
Fludarabine—Paraesthesia—Paclitaxel—kidney cancer	5.23e-05	0.000376	CcSEcCtD
Fludarabine—Vomiting—Dactinomycin—kidney cancer	5.22e-05	0.000375	CcSEcCtD
Fludarabine—Bronchitis—Doxorubicin—kidney cancer	5.21e-05	0.000375	CcSEcCtD
Fludarabine—Dyspnoea—Paclitaxel—kidney cancer	5.19e-05	0.000373	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	5.18e-05	0.00134	CbGpPWpGaD
Fludarabine—Rash—Dactinomycin—kidney cancer	5.17e-05	0.000372	CcSEcCtD
Fludarabine—Nausea—Sunitinib—kidney cancer	5.15e-05	0.00037	CcSEcCtD
Fludarabine—RRM1—Metabolism—CRABP1—kidney cancer	5.15e-05	0.00133	CbGpPWpGaD
Fludarabine—Pancytopenia—Doxorubicin—kidney cancer	5.14e-05	0.00037	CcSEcCtD
Fludarabine—Dyspepsia—Paclitaxel—kidney cancer	5.13e-05	0.000369	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—AURKA—kidney cancer	5.11e-05	0.00133	CbGpPWpGaD
Fludarabine—Cough—Capecitabine—kidney cancer	5.11e-05	0.000367	CcSEcCtD
Fludarabine—Dysuria—Doxorubicin—kidney cancer	5.07e-05	0.000364	CcSEcCtD
Fludarabine—Neutropenia—Doxorubicin—kidney cancer	5.07e-05	0.000364	CcSEcCtD
Fludarabine—Decreased appetite—Paclitaxel—kidney cancer	5.06e-05	0.000364	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Doxorubicin—kidney cancer	5.03e-05	0.000362	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Paclitaxel—kidney cancer	5.03e-05	0.000361	CcSEcCtD
Fludarabine—Fatigue—Paclitaxel—kidney cancer	5.02e-05	0.000361	CcSEcCtD
Fludarabine—Diarrhoea—Vincristine—kidney cancer	5.02e-05	0.000361	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	5.01e-05	0.0013	CbGpPWpGaD
Fludarabine—Asthenia—Gemcitabine—kidney cancer	4.99e-05	0.000359	CcSEcCtD
Fludarabine—Myalgia—Capecitabine—kidney cancer	4.99e-05	0.000358	CcSEcCtD
Fludarabine—Arthralgia—Capecitabine—kidney cancer	4.99e-05	0.000358	CcSEcCtD
Fludarabine—Constipation—Paclitaxel—kidney cancer	4.98e-05	0.000358	CcSEcCtD
Fludarabine—Pain—Paclitaxel—kidney cancer	4.98e-05	0.000358	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—BIRC5—kidney cancer	4.96e-05	0.00128	CbGpPWpGaD
Fludarabine—Discomfort—Capecitabine—kidney cancer	4.93e-05	0.000354	CcSEcCtD
Fludarabine—Pruritus—Gemcitabine—kidney cancer	4.92e-05	0.000354	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	4.91e-05	0.00127	CbGpPWpGaD
Fludarabine—POLA1—S Phase—MYC—kidney cancer	4.89e-05	0.00127	CbGpPWpGaD
Fludarabine—Hyperglycaemia—Doxorubicin—kidney cancer	4.89e-05	0.000351	CcSEcCtD
Fludarabine—Nausea—Dactinomycin—kidney cancer	4.87e-05	0.00035	CcSEcCtD
Fludarabine—Pneumonia—Doxorubicin—kidney cancer	4.86e-05	0.000349	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	4.85e-05	0.00126	CbGpPWpGaD
Fludarabine—Confusional state—Capecitabine—kidney cancer	4.82e-05	0.000346	CcSEcCtD
Fludarabine—Feeling abnormal—Paclitaxel—kidney cancer	4.8e-05	0.000345	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	4.79e-05	0.000344	CcSEcCtD
Fludarabine—RRM1—Metabolism—ITPR2—kidney cancer	4.78e-05	0.00124	CbGpPWpGaD
Fludarabine—Oedema—Capecitabine—kidney cancer	4.78e-05	0.000344	CcSEcCtD
Fludarabine—Diarrhoea—Gemcitabine—kidney cancer	4.76e-05	0.000342	CcSEcCtD
Fludarabine—Renal failure—Doxorubicin—kidney cancer	4.75e-05	0.000341	CcSEcCtD
Fludarabine—Infection—Capecitabine—kidney cancer	4.75e-05	0.000341	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	4.75e-05	0.00123	CbGpPWpGaD
Fludarabine—Neuropathy peripheral—Doxorubicin—kidney cancer	4.73e-05	0.00034	CcSEcCtD
Fludarabine—Stomatitis—Doxorubicin—kidney cancer	4.71e-05	0.000338	CcSEcCtD
Fludarabine—Urinary tract infection—Doxorubicin—kidney cancer	4.7e-05	0.000338	CcSEcCtD
Fludarabine—Nervous system disorder—Capecitabine—kidney cancer	4.69e-05	0.000337	CcSEcCtD
Fludarabine—Thrombocytopenia—Capecitabine—kidney cancer	4.68e-05	0.000336	CcSEcCtD
Fludarabine—Vomiting—Vincristine—kidney cancer	4.66e-05	0.000335	CcSEcCtD
Fludarabine—DCK—Metabolism—CA9—kidney cancer	4.66e-05	0.00121	CbGpPWpGaD
Fludarabine—Rash—Vincristine—kidney cancer	4.62e-05	0.000332	CcSEcCtD
Fludarabine—Hyperhidrosis—Capecitabine—kidney cancer	4.62e-05	0.000332	CcSEcCtD
Fludarabine—Dermatitis—Vincristine—kidney cancer	4.62e-05	0.000332	CcSEcCtD
Fludarabine—Haematuria—Doxorubicin—kidney cancer	4.61e-05	0.000331	CcSEcCtD
Fludarabine—Body temperature increased—Paclitaxel—kidney cancer	4.6e-05	0.000331	CcSEcCtD
Fludarabine—Headache—Vincristine—kidney cancer	4.59e-05	0.00033	CcSEcCtD
Fludarabine—Epistaxis—Doxorubicin—kidney cancer	4.56e-05	0.000328	CcSEcCtD
Fludarabine—Anorexia—Capecitabine—kidney cancer	4.56e-05	0.000327	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—MYC—kidney cancer	4.54e-05	0.00118	CbGpPWpGaD
Fludarabine—Sinusitis—Doxorubicin—kidney cancer	4.53e-05	0.000326	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	4.49e-05	0.00116	CbGpPWpGaD
Fludarabine—Vomiting—Gemcitabine—kidney cancer	4.42e-05	0.000318	CcSEcCtD
Fludarabine—Rash—Gemcitabine—kidney cancer	4.39e-05	0.000315	CcSEcCtD
Fludarabine—Dermatitis—Gemcitabine—kidney cancer	4.38e-05	0.000315	CcSEcCtD
Fludarabine—RRM1—Metabolism—ACHE—kidney cancer	4.36e-05	0.00113	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTT1—kidney cancer	4.36e-05	0.00113	CbGpPWpGaD
Fludarabine—Haemoglobin—Doxorubicin—kidney cancer	4.36e-05	0.000313	CcSEcCtD
Fludarabine—Headache—Gemcitabine—kidney cancer	4.36e-05	0.000313	CcSEcCtD
Fludarabine—Nausea—Vincristine—kidney cancer	4.36e-05	0.000313	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Capecitabine—kidney cancer	4.35e-05	0.000313	CcSEcCtD
Fludarabine—Haemorrhage—Doxorubicin—kidney cancer	4.34e-05	0.000312	CcSEcCtD
Fludarabine—Hypoaesthesia—Doxorubicin—kidney cancer	4.31e-05	0.00031	CcSEcCtD
Fludarabine—Pharyngitis—Doxorubicin—kidney cancer	4.3e-05	0.000309	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN2B—kidney cancer	4.3e-05	0.00111	CbGpPWpGaD
Fludarabine—Paraesthesia—Capecitabine—kidney cancer	4.29e-05	0.000309	CcSEcCtD
Fludarabine—Hypersensitivity—Paclitaxel—kidney cancer	4.29e-05	0.000308	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	4.29e-05	0.00111	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	4.28e-05	0.00111	CbGpPWpGaD
Fludarabine—Dyspnoea—Capecitabine—kidney cancer	4.26e-05	0.000306	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	4.25e-05	0.0011	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—RAF1—kidney cancer	4.24e-05	0.0011	CbGpPWpGaD
Fludarabine—Dyspepsia—Capecitabine—kidney cancer	4.21e-05	0.000302	CcSEcCtD
Fludarabine—Visual impairment—Doxorubicin—kidney cancer	4.18e-05	0.0003	CcSEcCtD
Fludarabine—Asthenia—Paclitaxel—kidney cancer	4.18e-05	0.0003	CcSEcCtD
Fludarabine—Decreased appetite—Capecitabine—kidney cancer	4.15e-05	0.000299	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	4.14e-05	0.00107	CbGpPWpGaD
Fludarabine—Nausea—Gemcitabine—kidney cancer	4.13e-05	0.000297	CcSEcCtD
Fludarabine—RRM1—Metabolism—SCARB1—kidney cancer	4.13e-05	0.00107	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Capecitabine—kidney cancer	4.13e-05	0.000297	CcSEcCtD
Fludarabine—Fatigue—Capecitabine—kidney cancer	4.12e-05	0.000296	CcSEcCtD
Fludarabine—Pruritus—Paclitaxel—kidney cancer	4.12e-05	0.000296	CcSEcCtD
Fludarabine—Erythema multiforme—Doxorubicin—kidney cancer	4.1e-05	0.000295	CcSEcCtD
Fludarabine—RRM1—Metabolism—PTGS1—kidney cancer	4.09e-05	0.00106	CbGpPWpGaD
Fludarabine—Pain—Capecitabine—kidney cancer	4.09e-05	0.000294	CcSEcCtD
Fludarabine—Constipation—Capecitabine—kidney cancer	4.09e-05	0.000294	CcSEcCtD
Fludarabine—RRM1—Metabolism—PSMD7—kidney cancer	4.01e-05	0.00104	CbGpPWpGaD
Fludarabine—Diarrhoea—Paclitaxel—kidney cancer	3.98e-05	0.000286	CcSEcCtD
Fludarabine—DCK—Metabolism—CRABP1—kidney cancer	3.96e-05	0.00103	CbGpPWpGaD
Fludarabine—Feeling abnormal—Capecitabine—kidney cancer	3.94e-05	0.000283	CcSEcCtD
Fludarabine—Chills—Doxorubicin—kidney cancer	3.89e-05	0.00028	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—BRCA2—kidney cancer	3.88e-05	0.001	CbGpPWpGaD
Fludarabine—Arrhythmia—Doxorubicin—kidney cancer	3.87e-05	0.000278	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—CDKN2B—kidney cancer	3.84e-05	0.000995	CbGpPWpGaD
Fludarabine—Alopecia—Doxorubicin—kidney cancer	3.83e-05	0.000275	CcSEcCtD
Fludarabine—RRM1—Metabolism—BCHE—kidney cancer	3.8e-05	0.000985	CbGpPWpGaD
Fludarabine—Body temperature increased—Capecitabine—kidney cancer	3.78e-05	0.000272	CcSEcCtD
Fludarabine—Malnutrition—Doxorubicin—kidney cancer	3.77e-05	0.000271	CcSEcCtD
Fludarabine—RRM1—Metabolism—SLC5A5—kidney cancer	3.75e-05	0.000973	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	3.74e-05	0.000969	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—BIRC5—kidney cancer	3.71e-05	0.000961	CbGpPWpGaD
Fludarabine—Vomiting—Paclitaxel—kidney cancer	3.7e-05	0.000266	CcSEcCtD
Fludarabine—DCK—Metabolism—ITPR2—kidney cancer	3.68e-05	0.000954	CbGpPWpGaD
Fludarabine—Rash—Paclitaxel—kidney cancer	3.67e-05	0.000264	CcSEcCtD
Fludarabine—Dermatitis—Paclitaxel—kidney cancer	3.67e-05	0.000264	CcSEcCtD
Fludarabine—Headache—Paclitaxel—kidney cancer	3.65e-05	0.000262	CcSEcCtD
Fludarabine—RRM1—Metabolism—SLC2A1—kidney cancer	3.63e-05	0.00094	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	3.54e-05	0.000916	CbGpPWpGaD
Fludarabine—Hypersensitivity—Capecitabine—kidney cancer	3.52e-05	0.000253	CcSEcCtD
Fludarabine—Ill-defined disorder—Doxorubicin—kidney cancer	3.5e-05	0.000252	CcSEcCtD
Fludarabine—Anaemia—Doxorubicin—kidney cancer	3.49e-05	0.000251	CcSEcCtD
Fludarabine—Agitation—Doxorubicin—kidney cancer	3.47e-05	0.000249	CcSEcCtD
Fludarabine—Nausea—Paclitaxel—kidney cancer	3.46e-05	0.000249	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	3.44e-05	0.000891	CbGpPWpGaD
Fludarabine—Asthenia—Capecitabine—kidney cancer	3.43e-05	0.000246	CcSEcCtD
Fludarabine—Malaise—Doxorubicin—kidney cancer	3.4e-05	0.000245	CcSEcCtD
Fludarabine—Pruritus—Capecitabine—kidney cancer	3.38e-05	0.000243	CcSEcCtD
Fludarabine—Leukopenia—Doxorubicin—kidney cancer	3.38e-05	0.000243	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	3.36e-05	0.000872	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTT1—kidney cancer	3.36e-05	0.00087	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ACHE—kidney cancer	3.36e-05	0.00087	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—BIRC5—kidney cancer	3.32e-05	0.000859	CbGpPWpGaD
Fludarabine—Cough—Doxorubicin—kidney cancer	3.29e-05	0.000237	CcSEcCtD
Fludarabine—Convulsion—Doxorubicin—kidney cancer	3.27e-05	0.000235	CcSEcCtD
Fludarabine—Diarrhoea—Capecitabine—kidney cancer	3.27e-05	0.000235	CcSEcCtD
Fludarabine—Myalgia—Doxorubicin—kidney cancer	3.21e-05	0.000231	CcSEcCtD
Fludarabine—Arthralgia—Doxorubicin—kidney cancer	3.21e-05	0.000231	CcSEcCtD
Fludarabine—DCK—Metabolism—SCARB1—kidney cancer	3.18e-05	0.000824	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	3.18e-05	0.000823	CbGpPWpGaD
Fludarabine—Discomfort—Doxorubicin—kidney cancer	3.18e-05	0.000228	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—RAF1—kidney cancer	3.16e-05	0.00082	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS1—kidney cancer	3.15e-05	0.000815	CbGpPWpGaD
Fludarabine—Confusional state—Doxorubicin—kidney cancer	3.11e-05	0.000223	CcSEcCtD
Fludarabine—DCK—Metabolism—PSMD7—kidney cancer	3.09e-05	0.0008	CbGpPWpGaD
Fludarabine—Anaphylactic shock—Doxorubicin—kidney cancer	3.08e-05	0.000221	CcSEcCtD
Fludarabine—Oedema—Doxorubicin—kidney cancer	3.08e-05	0.000221	CcSEcCtD
Fludarabine—Infection—Doxorubicin—kidney cancer	3.06e-05	0.00022	CcSEcCtD
Fludarabine—Vomiting—Capecitabine—kidney cancer	3.04e-05	0.000218	CcSEcCtD
Fludarabine—RRM1—Metabolism—GSTP1—kidney cancer	3.02e-05	0.000784	CbGpPWpGaD
Fludarabine—Nervous system disorder—Doxorubicin—kidney cancer	3.02e-05	0.000217	CcSEcCtD
Fludarabine—Thrombocytopenia—Doxorubicin—kidney cancer	3.02e-05	0.000217	CcSEcCtD
Fludarabine—Rash—Capecitabine—kidney cancer	3.01e-05	0.000217	CcSEcCtD
Fludarabine—Dermatitis—Capecitabine—kidney cancer	3.01e-05	0.000216	CcSEcCtD
Fludarabine—Headache—Capecitabine—kidney cancer	2.99e-05	0.000215	CcSEcCtD
Fludarabine—Hyperhidrosis—Doxorubicin—kidney cancer	2.98e-05	0.000214	CcSEcCtD
Fludarabine—Anorexia—Doxorubicin—kidney cancer	2.94e-05	0.000211	CcSEcCtD
Fludarabine—DCK—Metabolism—BCHE—kidney cancer	2.93e-05	0.000758	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	2.92e-05	0.000757	CbGpPWpGaD
Fludarabine—DCK—Metabolism—SLC5A5—kidney cancer	2.89e-05	0.000749	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ABCB1—kidney cancer	2.86e-05	0.000742	CbGpPWpGaD
Fludarabine—Nausea—Capecitabine—kidney cancer	2.84e-05	0.000204	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	2.82e-05	0.000732	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.81e-05	0.000202	CcSEcCtD
Fludarabine—DCK—Metabolism—SLC2A1—kidney cancer	2.79e-05	0.000723	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTM1—kidney cancer	2.78e-05	0.00072	CbGpPWpGaD
Fludarabine—Paraesthesia—Doxorubicin—kidney cancer	2.77e-05	0.000199	CcSEcCtD
Fludarabine—Dyspnoea—Doxorubicin—kidney cancer	2.75e-05	0.000197	CcSEcCtD
Fludarabine—Dyspepsia—Doxorubicin—kidney cancer	2.71e-05	0.000195	CcSEcCtD
Fludarabine—Decreased appetite—Doxorubicin—kidney cancer	2.68e-05	0.000193	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.66e-05	0.000191	CcSEcCtD
Fludarabine—Fatigue—Doxorubicin—kidney cancer	2.66e-05	0.000191	CcSEcCtD
Fludarabine—RRM1—Metabolism—CYP1A1—kidney cancer	2.63e-05	0.000683	CbGpPWpGaD
Fludarabine—Constipation—Doxorubicin—kidney cancer	2.63e-05	0.000189	CcSEcCtD
Fludarabine—Pain—Doxorubicin—kidney cancer	2.63e-05	0.000189	CcSEcCtD
Fludarabine—Feeling abnormal—Doxorubicin—kidney cancer	2.54e-05	0.000182	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—kidney cancer	2.46e-05	0.000637	CbGpPWpGaD
Fludarabine—Body temperature increased—Doxorubicin—kidney cancer	2.44e-05	0.000175	CcSEcCtD
Fludarabine—DCK—Metabolism—GSTP1—kidney cancer	2.33e-05	0.000603	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—MAPK3—kidney cancer	2.29e-05	0.000593	CbGpPWpGaD
Fludarabine—Hypersensitivity—Doxorubicin—kidney cancer	2.27e-05	0.000163	CcSEcCtD
Fludarabine—Asthenia—Doxorubicin—kidney cancer	2.21e-05	0.000159	CcSEcCtD
Fludarabine—DCK—Metabolism—ABCB1—kidney cancer	2.2e-05	0.000571	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN2A—kidney cancer	2.2e-05	0.000569	CbGpPWpGaD
Fludarabine—Pruritus—Doxorubicin—kidney cancer	2.18e-05	0.000157	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—MAPK1—kidney cancer	2.18e-05	0.000564	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN1B—kidney cancer	2.18e-05	0.000564	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTM1—kidney cancer	2.14e-05	0.000554	CbGpPWpGaD
Fludarabine—Diarrhoea—Doxorubicin—kidney cancer	2.11e-05	0.000152	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—CCND1—kidney cancer	2.08e-05	0.000538	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP1A1—kidney cancer	2.03e-05	0.000525	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—POMC—kidney cancer	1.96e-05	0.000509	CbGpPWpGaD
Fludarabine—Vomiting—Doxorubicin—kidney cancer	1.96e-05	0.000141	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—CDKN1B—kidney cancer	1.95e-05	0.000504	CbGpPWpGaD
Fludarabine—Rash—Doxorubicin—kidney cancer	1.94e-05	0.00014	CcSEcCtD
Fludarabine—Dermatitis—Doxorubicin—kidney cancer	1.94e-05	0.00014	CcSEcCtD
Fludarabine—Headache—Doxorubicin—kidney cancer	1.93e-05	0.000139	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—CCND1—kidney cancer	1.86e-05	0.000481	CbGpPWpGaD
Fludarabine—Nausea—Doxorubicin—kidney cancer	1.83e-05	0.000132	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—MAPK3—kidney cancer	1.71e-05	0.000444	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MYC—kidney cancer	1.67e-05	0.000431	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MAPK1—kidney cancer	1.63e-05	0.000422	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTGS2—kidney cancer	1.57e-05	0.000406	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MAPK3—kidney cancer	1.53e-05	0.000397	CbGpPWpGaD
Fludarabine—DCK—Metabolism—POMC—kidney cancer	1.51e-05	0.000392	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MYC—kidney cancer	1.49e-05	0.000386	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MAPK1—kidney cancer	1.46e-05	0.000377	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTEN—kidney cancer	1.37e-05	0.000354	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—kidney cancer	1.22e-05	0.000317	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS2—kidney cancer	1.21e-05	0.000312	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTEN—kidney cancer	1.05e-05	0.000272	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CA—kidney cancer	9.64e-06	0.00025	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CA—kidney cancer	7.42e-06	0.000192	CbGpPWpGaD
